HIMS Stock Just Exploded 40%, And the Company That Nearly Destroyed It Is Now Its Savior
The Novo Nordisk–Hims & Hers story has every twist of a Wall Street thriller. Here's the full breakdown.
The Short Version (For the "Just Tell Me What Happened" Crowd)
Most financial headlines are written like legal documents. So before we dive deep, here's the human version:
Hims & Hers Health (NYSE: HIMS), the telehealth company behind those sleek ads for hair loss, ED meds, and yes, weight-loss drugs, just got a massive lifeline. The company that was literally suing them last month? Novo Nordisk. The maker of Wegovy and Ozempic.
And now? They're apparently… partners again.
Hims stock surged 39% in after-hours trading Friday after Bloomberg reported that Novo Nordisk plans to sell its weight-loss drugs through Hims' telehealth platform, ending the legal dispute, including a patent infringement lawsuit filed by Novo just weeks ago.
That's not a typo. Thirty-nine percent. Overnight.
So what on earth is going on here? Pull up a chair.
How Did We Even Get Here? The Fall of HIMS
To understand why this news hit so hard, you need to know how badly things had unraveled for Hims over the past year.
This company had an incredible run. What began as a platform for hair-loss treatments, erectile dysfunction meds, and skincare evolved into a weight-loss powerhouse once GLP-1 agonists, the class of drugs that includes Wegovy and Ozempic, exploded in popularity.
During the shortage of Wegovy and Ozempic, Hims found a clever workaround: compounded versions. Basically, FDA-approved pharmacies could legally make their own version of semaglutide (the active ingredient in both drugs) while the branded stuff was backordered. Hims offered these versions at a fraction of the cost, and customers came flooding in.
But then… the walls started closing in.
Here's the timeline of what went wrong:
- April 2025: Novo Nordisk partnered with Hims, Ro, and LifeMD to sell Wegovy directly to cash-paying customers. Seemed great, right?
- June 2025: Novo abruptly terminated the deal, citing safety concerns over Hims' compounded products. The real hammer came next: Novo sued for patent infringement after Hims launched a $49 compounded oral pill mimicking Novo's new formulation.
- February 2026: Hims revealed the pending launch of a compounded form of Novo's drug semaglutide, priced at $49 for the first month and $99 in subsequent months, compared to Novo's original formula at more than $1,000 a month without insurance.
- The FDA threatened enforcement. Hims pulled the product. Novo sued. Regulators circled.
From its peak, the stock cratered 77%, wiping out billions in market value and leaving Hims staring at a future of slowed growth and limited upside without the GLP-1 tailwind.
Ouch. That's not a dip. That's a cliff.
So Why Is the Stock Exploding NOW?
Here's where it gets wild.
Novo Nordisk has reached a deal to sell its weight-loss drugs on Hims & Hers' online platform, one month after threatening legal action when the telehealth company announced plans to market a $49 copy of Novo's popular Wegovy obesity pill.
The announcement is expected as early as Monday, March 9th. No financial terms have been disclosed yet, which is worth noting, because we don't actually know the economics of this deal yet.
But Wall Street didn't wait around to find out. HIMS surged about 20% in overnight trading on Sunday, with a fund manager saying the stock could climb up to 60% on short covering.
Lupton Capital CEO Jonah Lupton suggested a 50–60% rally was entirely possible this week. And on Stocktwits, retail sentiment for HIMS was "extremely bullish" amid an 840% surge in message volume over the past week.
Translation: people are excited. Maybe too excited. But we'll get to that.
Why Would Novo Nordisk Do This?
Okay, so here's the question that's probably bugging you. Why would Novo partner with Hims after filing a patent lawsuit against them? Like… what changed?
Honestly? It's business strategy, and it makes a lot of sense when you zoom out.
Eli Lilly's Zepbound has been stealing market share with superior efficacy data and aggressive marketing. Novo's response includes its new oral obesity pill, designed to broaden access and reduce injection fatigue. Distributing branded versions through Hims' massive telehealth audience gives Novo instant scale without building its own direct-to-consumer infrastructure.
Think about it from Novo's perspective. They've got a blockbuster drug. They need it in front of as many paying customers as possible, fast. Hims already has the distribution network, the brand recognition, and millions of subscribers who want weight-loss solutions.
A Novo spokesperson said the company is "always in conversation with companies that can help improve patient access to FDA-approved medicines."
That's very diplomatically worded. But what it really means is: the obesity drug market is heating up, and Novo needs every advantage it can get.
What Does This Mean for HIMS Financially?
Let's talk numbers for a second, because the stock price is one thing, but the fundamentals matter too.
Hims reported 2025 revenue jumping 59% to around $2.35 billion, adding that its 2026 outlook counted on continued access to compounded semaglutide.
That last part is key. The entire 2026 revenue guidance was built around being able to keep selling compounded versions. That's now in serious jeopardy, or at least, it's changing shape dramatically.
Management guided to $2.7–2.9 billion in sales for 2026. That outlook was set before the branded GLP-1 deal and was based on a mix of weight loss, sexual health, and newer offerings like lab testing and cancer screening.
Hims & Hers' weight loss business is on pace to bring in $725 million in revenue in 2025, according to CFO Yemi Okupe.
That's a significant chunk. And the Novo partnership directly affects how that revenue is generated going forward, shifting from cheap compounded drugs to branded Wegovy at much higher price points. Whether that's better or worse for margins? We genuinely don't know yet.
The Risks Nobody's Talking About (But Should Be)
Look, I'm not here to rain on anyone's parade. But if you're thinking about jumping into HIMS stock based on this news, there are a few things worth sitting with.
Risk #1: We've been here before.
This is the second time the companies have danced, only for Novo to walk away when it suited its interests. Back in April 2025, Novo announced plans to collaborate with Hims, Ro, and LifeMD, allowing each to offer Wegovy directly to cash-paying U.S. buyers. Just two months later, Novo cut ties with Hims, citing issues over its marketing and its ongoing sale of Wegovy knockoffs.
Two months. That's how long the first partnership lasted. What's different this time?
Risk #2: The compounding business is basically gone.
The FDA crackdown on compounded GLP-1 drugs was already underway. The FDA recently issued warning letters to about 30 telehealth companies over misleading marketing tied to compounded GLP-1 drugs such as Semaglutide, Tirzepatide, and Liraglutide. Hims built a huge chunk of its recent growth on that business. That revenue doesn't automatically get replaced 1:1 with branded Wegovy sales.
Risk #3: The financial terms are unknown.
This is a big one. Financial terms of the arrangement were not disclosed. If Novo is taking a large cut, or if Hims' margins on branded Wegovy are thin, the economics might not be as rosy as the stock price reaction suggests.
Risk #4: Execution is hard.
The Novo Nordisk partnership directly reshapes the key short-term catalyst around GLP-1 weight loss by moving from compounded to branded drugs, while the biggest current risk remains regulatory and supply exposure tied to obesity medications.
Transitioning a business model mid-flight is genuinely difficult. The customers who came to Hims for $49 semaglutide aren't necessarily the same customers willing to pay Wegovy prices.
What Analysts Are Saying
Wall Street's reaction has been cautiously optimistic, emphasis on cautiously.
Leerink Partners analyst Michael Cherny said: "There is no other way to describe the Hims news as both a surprise and an unabashed positive for Hims' stock."
Leerink also noted that Novo has been expanding distribution partnerships broadly, pointing to deals with digital pharmacies and CVS as context for why this move fits Novo's strategy.
Needham's Ryan MacDonald had previously noted that Hims would be "looking at the market from the outside" if it couldn't secure a branded weight-loss drug. This deal, then, is Hims getting back in the room.
What Happens Next?
Here's what to watch over the coming weeks:
- The formal announcement, terms, product lineup, and launch timeline will be critical
- How Hims addresses compounded semaglutide customers, will they migrate them to Wegovy, or lose them?
- FDA regulatory environment, the crackdown on compounding isn't over
- Earnings on May 4, 2026, this will be the first real look at how the deal is performing
- Eli Lilly's response, Zepbound isn't going anywhere, and this partnership makes Hims a stronger Novo ally
Here's what I keep coming back to: this is a genuinely fascinating business story, regardless of whether you own a single share.
A telehealth company built its growth on selling cheap versions of a blockbuster drug. The drug maker sued them. Then… offered them a partnership.
What looked like a slow death by regulatory pressure and lost momentum has suddenly become a second act. Novo Nordisk, once Hims' aggressor, is now its savior.
For investors, the question isn't whether this is good news, it clearly is, in the short term. The real question is whether this partnership is durable, whether the business model transition works, and whether Hims can avoid the same mistakes that got them here in the first place.
That's not a question the stock price can answer. That's one you'll have to watch play out.
Are you watching HIMS stock this week? Drop your thoughts in the comments, whether you're bullish, bearish, or just fascinated by the drama. And if you want to stay on top of the latest moves in health-tech stocks, GLP-1 market developments, and telehealth trends, subscribe to our newsletter for weekly breakdowns that actually make sense.
(Not financial advice. Always do your own research before making investment decisions.)